Esteve and Boehringer Ingelheim have reached an agreement whereby they enter into a joint promotion to share their commitment to improving the lives of patients with non-valvular atrial fibrillation (NVAF) at risk of suffering a stroke. In June 2012, Esteve has moved its Center for Drug Discovery and Preclinical Development to the Barcelona Science Park (PCB) in an attempt to shorten development time and speed up the arrival to market of innovative new drugs. 

800,000 people in Spain take anticoagulants to prevent stroke. Each year, 120,000 to 130,000 people suffer this disease.The two companies will simultaneously promote two treatments from Boehringer Ingelheim using the only direct oral anticoagulant with rapid reversal. 

Boehringer Ingelheim and Esteve have reached an agreement  after their first experience in respiratory care  undertaken with the same purpose and in the same year.

The two managing directors concurred: “It’s a great opportunity”. Timmo Andersen, managing director of Boehringer Ingelheim Spain, emphasized that “this agreement represents a collective challenge and is yet another demonstration of innovation, commitment and value by the two companies, always bearing in mind the benefit this has in patients with cardiovascular diseases”.

In the words of Joseph Sullivan, managing director of Esteve Farma, “By placing its trust in our company again, Boehringer Ingelheim’s helps us keep securing a wide range of solutions to help professionals better manage patient problems as well as to provide response to unmet medical needs.”